Antonios Aliprantis Starts New Role as Head of Immunology Early Development Innovation and Strategy at Biogen
Antonios Aliprantis/LinkedIn

Antonios Aliprantis Starts New Role as Head of Immunology Early Development Innovation and Strategy at Biogen

Antonios Aliprantis, Head of Immunology Early Development Innovation and Strategy at Biogen, shared on LinkedIn:

“I am excited to share my new role at Biogen as Head of Immunology Early Development Innovation and Strategy after a wonderful 5 years at Flagship Pioneering and Pioneering Medicines.

I’ll be forever grateful for the last 5 years at Flagship Pioneering where I got to work alongside renowned company creators and seasoned R&D leaders to help transform breakthrough platform science into novel therapies for patients.

There are too many people to thank individually but Paul Biondi – thank you for being such a champion of my career at FSP.

Now I’m on to Biogen, a company with a deep legacy of addressing the needs of patients with the most difficult to treat conditions.

I’m thrilled to work with their team to leverage cutting edge science to drive a pipeline of medicines for patients struggling with challenging immunologic diseases.”

Other articles featuring Antonios Aliprantis on OncoDaily.